IDEX Corporation (IEX) Income Statement

The sequential acceleration from 4.2% to 6.4% growth, coupled with record orders, indicates that the organic growth initiatives are gaining traction. The HST segment's exposure to life sciences and FMT's steady industrial base appear to be driving this momentum, though the sustainability hinges on continued biopharma spending and municipal budgets.

The 110 basis point year-over-year expansion suggests that higher-margin HST products are becoming a larger revenue component, supported by the '80/20' efficiency program. However, the 2024Q4 margin collapse to 38.8% indicates that input cost spikes or mix shifts can quickly erode gains, warranting close monitoring of raw material costs and segment mix.

The near-stable operating margin despite revenue growth suggests that SG&A is being managed tightly, with the 2026Q2 SG&A-to-revenue ratio at 24.3% versus 23.3% in 2025Q2. This implies that the company is not scaling overhead proportionally, which could support further margin expansion if revenue growth persists.

The reduction in COGS ratio suggests improved input cost management or favorable pricing, but the 10.9% SG&A increase outpaces revenue growth, indicating deliberate investment in sales and R&D. This could pressure near-term margins if revenue growth decelerates, though it may be necessary to sustain the order momentum.

The sharp margin contraction in 2024Q4 likely reflected input cost inflation or unfavorable mix, but the subsequent recovery indicates that management's pricing actions and '80/20' pruning have restored profitability. This inflection underscores the company's ability to navigate cost shocks, though the sustainability of the recovery depends on end-market stability.